XTL Biopharmaceuticals Ltd Total Assets
XTL Biopharmaceuticals Ltd total assets. Based on the latest financial reports, XTL Biopharmaceuticals Ltd (H2K2) holds total assets worth €8.55 Million EUR (≈ $10.00 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see H2K2 company net worth for the company's overall valuation and market capitalisation.
Total Assets of XTL Biopharmaceuticals Ltd (2016–2024)
Total assets of XTL Biopharmaceuticals Ltd from 2016 to 2024. This chart illustrates how XTL Biopharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data. See H2K2 share price today for real-time trading data and today's change.
XTL Biopharmaceuticals Ltd - Asset Composition Analysis
XTL Biopharmaceuticals Ltd Total Assets Breakdown (December 2024)
XTL Biopharmaceuticals Ltd total assets breakdown as of December 2024. XTL Biopharmaceuticals Ltd's total assets of €8.55 Million consist of 15.7% current assets and 84.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.3% |
| Accounts Receivable | €99.00K | 1.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.82 Million | 44.6% |
| Goodwill | €3.19 Million | 37.4% |
Asset Composition Trend (2016–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of XTL Biopharmaceuticals Ltd to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: XTL Biopharmaceuticals Ltd's current assets represent 15.7% of total assets in 2024, a decrease from 91.3% in 2016.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2024, down from 66.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 8.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 44.6% of total assets.
XTL Biopharmaceuticals Ltd Competitors by Total Assets
Key competitors of XTL Biopharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
XTL Biopharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.61 | 9.93 | 28.23 |
| Quick Ratio | 0.61 | 9.93 | 28.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-867.00K | €1.84 Million | €6.64 Million |
XTL Biopharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between XTL Biopharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 252.4% |
| Total Assets | €8.55 Million |
| Market Capitalization | $1.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values XTL Biopharmaceuticals Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: XTL Biopharmaceuticals Ltd's assets grew by 252.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for XTL Biopharmaceuticals Ltd (2016–2024)
The table below shows the annual total assets of XTL Biopharmaceuticals Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €8.55 Million ≈ $10.00 Million |
+252.43% |
| 2023-12-31 | €2.43 Million ≈ $2.84 Million |
-42.04% |
| 2022-12-31 | €4.19 Million ≈ $4.89 Million |
-36.75% |
| 2021-12-31 | €6.62 Million ≈ $7.74 Million |
+1.77% |
| 2020-12-31 | €6.50 Million ≈ $7.60 Million |
-9.83% |
| 2019-12-31 | €7.21 Million ≈ $8.43 Million |
-15.90% |
| 2018-12-31 | €8.57 Million ≈ $10.03 Million |
+30.20% |
| 2017-12-31 | €6.59 Million ≈ $7.70 Million |
+118.30% |
| 2016-12-31 | €3.02 Million ≈ $3.53 Million |
-- |
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more